Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
Add more filters










Publication year range
1.
J Phys Chem Lett ; 12(45): 11070-11077, 2021 Nov 18.
Article in English | MEDLINE | ID: mdl-34748341

ABSTRACT

Epigenetic DNA modifications play a fundamental role in modulating gene expression and regulating cellular and developmental biological processes, thereby forming a second layer of information in DNA. The epigenetic 2'-deoxycytidine modification 5-methyl-2'-deoxycytidine, together with its enzymatic oxidation products (5-hydroxymethyl-2'-deoxycytidine, 5-formyl-2'-deoxycytidine, and 5-carboxyl-2'-deoxycytidine), are closely related to deactivation and reactivation of DNA transcription. Here, we combine sub-30-fs transient absorption spectroscopy with high-level correlated multiconfigurational CASPT2/MM computational methods, explicitly including the solvent, to obtain a unified picture of the photophysics of deoxycytidine-derived epigenetic DNA nucleosides. We assign all the observed time constants and identify the excited state relaxation pathways, including the competition of intersystem crossing and internal conversion for 5-formyl-2'-deoxycytidine and ballistic decay to the ground state for 5-carboxy-2'-deoxycytidine. Our work contributes to shed light on the role of epigenetic derivatives in DNA photodamage as well as on their possible therapeutic use.


Subject(s)
DNA/genetics , Deoxycytidine/genetics , Epigenesis, Genetic/genetics , Deoxycytidine/analogs & derivatives , Deoxycytidine/chemistry , Nucleic Acid Conformation
2.
J Am Chem Soc ; 140(36): 11464-11473, 2018 09 12.
Article in English | MEDLINE | ID: mdl-30160955

ABSTRACT

Almost five decades ago Crick, Orgel, and others proposed the RNA world hypothesis. Subsequent studies have raised the possibility that RNA might be able to support both genotype and phenotype, and the function of RNA templates has been studied in terms of evolution, replication, and catalysis. Recently, we engineered strains of E. coli in which a large fraction of 2'-deoxycytidine in the genome is substituted with the modified base 5-hydroxymethyl-2'-deoxycytidine. We now report the generation of mutant strains derived from these engineered bacteria that show significant (∼40-50%) ribonucleotide content in their genome. We have begun to characterize the properties of these chimeric genomes and the corresponding strains to determine the circumstances under which E. coli can incorporate ribonucleotides into its genome and herein report our initial observations.


Subject(s)
DNA, Bacterial/genetics , Escherichia coli/genetics , Genome, Bacterial/genetics , RNA, Bacterial/genetics , Base Sequence , Deoxycytidine/analogs & derivatives , Deoxycytidine/chemistry , Deoxycytidine/genetics , Molecular Structure
3.
Mem Inst Oswaldo Cruz ; 112(11): 785-789, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29091140

ABSTRACT

Cytidine deaminase (MtCDA), encoded by cdd gene (Rv3315c), is the only enzyme identified in nucleotide biosynthesis pathway of Mycobacterium tuberculosis that is able to recycle cytidine and deoxycytidine. An M. tuberculosis knockout strain for cdd gene was obtained by allelic replacement. Evaluation of mRNA expression validated cdd deletion and showed the absence of polar effect. MudPIT LC-MS/MS data indicated thymidine phosphorylase expression was decreased in knockout and complemented strains. The cdd disruption does not affect M. tuberculosis growth both in Mid- dlebrook 7H9 and in RAW 264.7 cells, which indicates that cdd is not important for macrophage invasion and virulence.


Subject(s)
Cytidine Deaminase/genetics , Deoxycytidine/genetics , Macrophages/microbiology , Mycobacterium tuberculosis/pathogenicity , Cytidine Deaminase/biosynthesis , Deoxycytidine/biosynthesis , Gene Knockout Techniques , Humans , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/growth & development , Time Factors
4.
Mem. Inst. Oswaldo Cruz ; 112(11): 785-789, Nov. 2017. graf
Article in English | LILACS | ID: biblio-1040564

ABSTRACT

Cytidine deaminase (MtCDA), encoded by cdd gene (Rv3315c), is the only enzyme identified in nucleotide biosynthesis pathway of Mycobacterium tuberculosis that is able to recycle cytidine and deoxycytidine. An M. tuberculosis knockout strain for cdd gene was obtained by allelic replacement. Evaluation of mRNA expression validated cdd deletion and showed the absence of polar effect. MudPIT LC-MS/MS data indicated thymidine phosphorylase expression was decreased in knockout and complemented strains. The cdd disruption does not affect M. tuberculosis growth both in Mid- dlebrook 7H9 and in RAW 264.7 cells, which indicates that cdd is not important for macrophage invasion and virulence.


Subject(s)
Humans , Cytidine Deaminase/genetics , Deoxycytidine/genetics , Macrophages/microbiology , Mycobacterium tuberculosis/pathogenicity , Time Factors , Cytidine Deaminase/biosynthesis , Deoxycytidine/biosynthesis , Gene Knockout Techniques , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/enzymology
5.
Biosens Bioelectron ; 98: 210-214, 2017 Dec 15.
Article in English | MEDLINE | ID: mdl-28683413

ABSTRACT

We develop a novel approach to determine formamidopyrimidine DNA glycosylase (Fpg) activity by taking advantage of the unique fluorescence property of pyrrolo-dC (PdC) positioned opposite to 8-oxoguanine (8-oxoG) in duplex DNA. In its initial state, PdC in duplex DNA undergoes the efficient stacking and collisional quenching interactions, showing the low fluorescence signal. In contrast, the presence of Fpg, which specifically removes 8-oxoG and incises resulting apurinic (AP) site, transforms duplex DNA into single-stranded (ss) DNAs. As a result, the intrinsic fluorescence signal of PdC in ssDNA is recovered to exhibit the significantly enhanced fluorescence signal. Based on this Fpg-dependent fluorescence response of PdC, we could reliably determine Fpg activity down to 1.25U/ml with a linear response from 0 to 50U/ml. In addition, the diagnostic capability of this strategy was successfully demonstrated by reliably assaying Fpg activity in human blood serum, showing its great potential in the practical applications.


Subject(s)
Biosensing Techniques , DNA-Formamidopyrimidine Glycosylase/isolation & purification , DNA/chemistry , Deoxycytidine/analogs & derivatives , Escherichia coli Proteins/isolation & purification , Pyrroles/chemistry , DNA/genetics , DNA Repair/genetics , DNA, Single-Stranded/chemistry , DNA, Single-Stranded/genetics , Deoxycytidine/chemistry , Deoxycytidine/genetics , Escherichia coli/enzymology , Fluorescence , Substrate Specificity
6.
Anal Chem ; 88(7): 3476-80, 2016 Apr 05.
Article in English | MEDLINE | ID: mdl-26943016

ABSTRACT

DNA hydroxymethylation (5-hmC) is a kind of new epigenetic modification, which plays key roles in DNA demethylation, genomic reprogramming, and the gene expression in mammals. For further exploring the functions of 5-hmC, it is necessary to develop sensitive and selective methods for detecting 5-hmC. Herein, we developed a novel multiplexing electrochemical (MEC) biosensor for 5-hmC detection based on the glycosylation modification of 5-hmC and enzymatic signal amplification. The 5-hmC was first glycosylated by T4 ß-glucosyltransferase and then oxidated by sodium periodate. The resulting glucosyl-modified 5-hmC (5-ghmC) was incubated with ARP-biotin and was bound to avidin-HRP. The 5-hmC can be detected at the subnanogram level. Finally, we performed 5-hmC detection for mouse tissue samples and cancer cell lines. The limit of detection of the MEC biosensor is 20 times lower than that of commercial kits based on optical meaurement. Also, the biosensor presented high detection specificity because the chemical reaction for 5-hmC modification can not happen at any other unhydroxymethylated nucleic acid bases. Importantly, benefited by its multiplexing capacity, the developed MEC biosensor showed excellent high efficiency, which was time-saving and cost less.


Subject(s)
Biosensing Techniques , DNA/chemistry , DNA/metabolism , Deoxycytidine/analogs & derivatives , Electrochemical Techniques , Genomics , Animals , Bacteriophage T4/enzymology , Biosensing Techniques/economics , Cell Line, Tumor , DNA Methylation , Deoxycytidine/analysis , Deoxycytidine/genetics , Deoxycytidine/metabolism , Electrochemical Techniques/economics , Epigenesis, Genetic , Glucosyltransferases/metabolism , Glycosylation , Humans , Limit of Detection , Mice , Oxidation-Reduction , Periodic Acid/chemistry
7.
Pharmacogenet Genomics ; 25(6): 317-21, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25850965

ABSTRACT

Azacytidine, an antimetabolite with an original epigenetic mechanism of action, increases survival in patients diagnosed with high-risk myelodysplasic syndromes or acute myeloid leukemia with less than 30% medullar blasts. Azacytidine is a pyrimidine derivative that undergoes metabolic detoxification driven by cytidine deaminase (CDA), a liver enzyme whose gene is prone to genetic polymorphism, leading to erratic activity among patients. Clinical reports have shown that patients with the poor metabolizer (PM) phenotype are likely to experience early severe or lethal toxicities when treated with nucleosidic analogs such as gemcitabine or cytarabine. No clinical data have been available thus far on the relationships between CDA PM status and toxicities in azacytidine-treated patients. Here, we measured CDA activity in a case of severe toxicities with fatal outcome in a patient undergoing standard azacytidine treatment. Results showed that the patient was PM (i.e. residual activity reduced by 63%), thus suggesting that an impaired detoxification step could have given rise to the lethal toxicities observed. This case report calls for further prospective studies investigating the exact role that CDA status plays in the clinical outcome of patients treated with azacytidine.


Subject(s)
Azacitidine/adverse effects , Cytidine Deaminase/genetics , Leukemia, Myeloid, Acute/genetics , Myelodysplastic Syndromes/genetics , Antimetabolites, Antineoplastic/adverse effects , Cytarabine/adverse effects , Cytarabine/toxicity , Cytidine Deaminase/deficiency , Deoxycytidine/adverse effects , Deoxycytidine/analogs & derivatives , Deoxycytidine/genetics , Fatal Outcome , Humans , Inactivation, Metabolic/genetics , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Myelodysplastic Syndromes/chemically induced , Myelodysplastic Syndromes/mortality , Polymorphism, Single Nucleotide , Gemcitabine
8.
Anal Bioanal Chem ; 407(9): 2423-31, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25142048

ABSTRACT

Epigenetic alterations are increasingly implicated in the initiation and progression of cancer. Genome-wide (global) hypomethylation seems to occur in early neoplasia and is a feature of genomic DNA derived from solid tumour tissues like ovarian cancer. Thus, analytical methods that provide sensitive and quantitative information about cytosine methylation in DNA are currently required. In this work, we compare two different anion-exchange columns for the separation of methylated cytosine from the other DNA nucleotides: a silica-based (Tracer Extrasil SAX) column and a polystyrene/divinyl benzene-based (Mono-Q™) column. Under the optimised conditions, linearity range, precision and detection limits of the developed high-performance liquid chromatography (HPLC) method were evaluated and compared using conventional ultraviolet (UV) absorbance detection at 270 nm. Good separation of the five target nucleotides, including 5-methyl-2'-deoxycytidine monophosphate (5mdCMP) and 2'-deoxycytidine monophosphate (dCMP) was achieved on the Mono-Q™ column with a gradient elution of ammonium acetate buffer (1 M, pH 6.9) at a flow rate of 1 mL min(-1). The coupling of this column to inductively coupled plasma mass spectrometry (ICP-MS) permitted also phosphorous ((31)P) specific detection of the nucleotides. Both detection systems offered adequate analytical performance characteristics, with detection limits of 30 and 40 µg L(-1) for 5mdCMP by HPLC-UV and HPLC-ICP-MS, respectively. However, the latter method allowed the determination of the global DNA methylation level (%) without the need for external calibration. Different genomic DNA samples were analysed including calf thymus DNA and DNA from two human cancer cell lines (adenocarcinoma epithelial A549 and ovarian carcinoma A2780) using the proposed strategy. In the line A2780, the cisplatin-sensitive and cisplatin-resistant variants were analysed, finding no significant differences in the methylation percentage after treatment with cisplatin.


Subject(s)
Antineoplastic Agents/pharmacology , Chromatography, Ion Exchange/methods , Cisplatin/pharmacology , Deoxycytidine/analogs & derivatives , Ovarian Neoplasms/genetics , Anion Exchange Resins/chemistry , Cell Line, Tumor , Chromatography, Ion Exchange/instrumentation , DNA Methylation , Deoxycytidine/chemistry , Deoxycytidine/genetics , Deoxycytidine/metabolism , Female , Humans , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/metabolism
9.
Nature ; 507(7491): 258-261, 2014 Mar 13.
Article in English | MEDLINE | ID: mdl-24531762

ABSTRACT

RNA interference is widely distributed in eukaryotes and has a variety of functions, including antiviral defence and gene regulation. All RNA interference pathways use small single-stranded RNA (ssRNA) molecules that guide proteins of the Argonaute (Ago) family to complementary ssRNA targets: RNA-guided RNA interference. The role of prokaryotic Ago variants has remained elusive, although bioinformatics analysis has suggested their involvement in host defence. Here we demonstrate that Ago of the bacterium Thermus thermophilus (TtAgo) acts as a barrier for the uptake and propagation of foreign DNA. In vivo, TtAgo is loaded with 5'-phosphorylated DNA guides, 13-25 nucleotides in length, that are mostly plasmid derived and have a strong bias for a 5'-end deoxycytidine. These small interfering DNAs guide TtAgo to cleave complementary DNA strands. Hence, despite structural homology to its eukaryotic counterparts, TtAgo functions in host defence by DNA-guided DNA interference.


Subject(s)
Argonaute Proteins/metabolism , DNA Cleavage , DNA/metabolism , Gene Silencing , Prokaryotic Cells/metabolism , Thermus thermophilus/genetics , Thermus thermophilus/metabolism , Base Pairing/genetics , Base Sequence , DNA/genetics , Deoxycytidine/genetics , Deoxycytidine/metabolism , Phosphorylation , Plasmids/genetics
10.
PLoS One ; 8(12): e84620, 2013.
Article in English | MEDLINE | ID: mdl-24391970

ABSTRACT

Epigenetic regulations play important roles in plant development and adaptation to environmental stress. Recent studies from mammalian systems have demonstrated the involvement of ten-eleven translocation (Tet) family of dioxygenases in the generation of a series of oxidized derivatives of 5-methylcytosine (5-mC) in mammalian DNA. In addition, these oxidized 5-mC nucleobases have important roles in epigenetic remodeling and aberrant levels of 5-hydroxymethyl-2'-deoxycytidine (5-HmdC) were found to be associated with different types of human cancers. However, there is a lack of evidence supporting the presence of these modified bases in plant DNA. Here we reported the use of a reversed-phase HPLC coupled with tandem mass spectrometry method and stable isotope-labeled standards for assessing the levels of the oxidized 5-mC nucleosides along with two other oxidatively induced DNA modifications in genomic DNA of Arabidopsis. These included 5-HmdC, 5-formyl-2'-deoxycytidine (5-FodC), 5-carboxyl-2'-deoxycytidine (5-CadC), 5-hydroxymethyl-2'-deoxyuridine (5-HmdU), and the (5'S) diastereomer of 8,5'-cyclo-2'-deoxyguanosine (S-cdG). We found that, in Arabidopsis DNA, the levels of 5-HmdC, 5-FodC, and 5-CadC are approximately 0.8 modifications per 10(6) nucleosides, with the frequency of 5-HmdC (per 5-mdC) being comparable to that of 5-HmdU (per thymidine). The relatively low levels of the 5-mdC oxidation products suggest that they arise likely from reactive oxygen species present in cells, which is in line with the lack of homologous Tet-family dioxygenase enzymes in Arabidopsis.


Subject(s)
Arabidopsis/chemistry , DNA, Plant/chemistry , Deoxycytidine/analogs & derivatives , Epigenesis, Genetic/physiology , Nucleosides/metabolism , Arabidopsis/physiology , Chromatography, High Pressure Liquid , Deoxycytidine/chemistry , Deoxycytidine/genetics , Deoxycytidine/metabolism , Deoxycytidine Monophosphate/analogs & derivatives , Deoxycytidine Monophosphate/chemistry , Deoxycytidine Monophosphate/metabolism , Epigenesis, Genetic/genetics , Fluoresceins/chemistry , Fluoresceins/metabolism , Isotope Labeling , Molecular Structure , Oxidation-Reduction , Tandem Mass Spectrometry , Thymidine/analogs & derivatives , Thymidine/chemistry , Thymidine/metabolism
12.
PLoS One ; 7(4): e34262, 2012.
Article in English | MEDLINE | ID: mdl-22493684

ABSTRACT

Recently, structural variation in the genome has been implicated in many complex diseases. Using genomewide single nucleotide polymorphism (SNP) arrays, researchers are able to investigate the impact not only of SNP variation, but also of copy-number variants (CNVs) on the phenotype. The most common analytic approach involves estimating, at the level of the individual genome, the underlying number of copies present at each location. Once this is completed, tests are performed to determine the association between copy number state and phenotype. An alternative approach is to carry out association testing first, between phenotype and raw intensities from the SNP array at the level of the individual marker, and then aggregate neighboring test results to identify CNVs associated with the phenotype. Here, we explore the strengths and weaknesses of these two approaches using both simulations and real data from a pharmacogenomic study of the chemotherapeutic agent gemcitabine. Our results indicate that pooled marker-level testing is capable of offering a dramatic increase in power (> 12-fold) over CNV-level testing, particularly for small CNVs. However, CNV-level testing is superior when CNVs are large and rare; understanding these tradeoffs is an important consideration in conducting association studies of structural variation.


Subject(s)
DNA Copy Number Variations/genetics , Genome-Wide Association Study/statistics & numerical data , Polymorphism, Single Nucleotide/genetics , Algorithms , Computer Simulation , Data Interpretation, Statistical , Deoxycytidine/analogs & derivatives , Deoxycytidine/genetics , Deoxycytidine/pharmacology , Genetic Markers , Genetic Variation , Genome, Human , Genotype , Humans , Oligonucleotide Array Sequence Analysis , Pharmacogenetics/statistics & numerical data , Phenotype , Gemcitabine
13.
Cancer ; 116(22): 5325-35, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20665488

ABSTRACT

BACKGROUND: It has not been well established whether genetic variations can be biomarkers for clinical outcome of gemcitabine therapy. The purpose of this study was to identify single nucleotide polymorphisms (SNPs) of gemcitabine metabolic and transporter genes that are associated with toxicity and efficacy of gemcitabine-based therapy in patients with locally advanced pancreatic cancer. METHODS: The authors evaluated 17 SNPs of the CDA,dCK, DCTD, RRM1, hCNT1-3, and hENT1 genes in 149 patients with locally advanced pancreatic cancer who underwent gemcitabine-based chemoradiotherapy. The association of genotypes with neutropenia, tumor response to therapy, overall survival, and progression-free survival (PFS) was analyzed by logistic regression, log-rank test, Kaplan-Meier plot, and Cox proportional hazards regression. RESULTS: The CDA A-76C, dCK C-1205T, RRM1 A33G, and hENT1 C913T genotypes were significantly associated with grade 3 to 4 neutropenia (P = .020, .015, .003, and .017, respectively).The CDA A-76C and hENT1 A-201G genotypes were significantly associated with tumor response to therapy (P = .017 and P = .019). A combined genotype effect of CDA A-76C, RRM1 A33G, RRM1 C-27A, and hENT1 A-201G on PFS was observed. Patients carrying 0 to 1 (n = 64), 2 (n = 50), or 3 to 4 (n = 17) at-risk genotypes had median PFS times of 8.3, 6.0, and 4.2 months, respectively (P = .002). CONCLUSIONS: The results indicated that some polymorphic variations of drug metabolic and transporter genes may be potential biomarkers for clinical outcome of gemcitabine-based therapy in patients with locally advanced pancreatic cancer.


Subject(s)
Deoxycytidine/analogs & derivatives , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/genetics , Polymorphism, Single Nucleotide , Aged , Deoxycytidine/adverse effects , Deoxycytidine/genetics , Deoxycytidine/metabolism , Deoxycytidine/therapeutic use , Disease-Free Survival , Eukaryotic Initiation Factor-3/analysis , Female , Gene Expression Profiling , Genotype , Humans , Male , Middle Aged , Pancreatic Neoplasms/mortality , Gemcitabine
14.
Oncol Res ; 18(1): 41-5, 2009.
Article in English | MEDLINE | ID: mdl-19911703

ABSTRACT

Transforming growth factor-beta (TGF-beta) family members are multifunctional cytokines that play a key role in cellular growth, proliferation, and differentiation. The aim of study was to evaluate the association of TGF-beta1 -509 C>T gene polymorphism with risk of cervical cancer. The study was carried out in 150 histopathology confirmed patients with cervical cancer and 162 cervical-cytology negative females. Polymorphisms for TGF-beta1 -509C>T gene was genotyped by polymerase chain reaction and restriction enzyme digestion. Frequencies of individuals with -509TT genotype and T allele of TGF-beta1 gene polymorphisms did not differ significantly in patients with cervical cancer and controls (p = 0.328, OR = 1.37 and p = 0.605, OR = 1.09). Cervical cancer patients with -509TT had marginal low risk for stage I (p = 0.04, OR = 0.95, 95% CI = 0.91-0.99) but -509TT genotype of TGF-beta1 was associated with increased risk of stage II of cancer (p = 0.07, OR = 3.13, 95% CI = 0.87-11.14). In gene-environment interaction, carriers of TGF-beta1 -509TT genotype with tobacco usage were at higher risk of cervical cancer (OR = 3.67, 95% CI = 0.38-35.1). In conclusion, our data suggest that TGF-beta1 -509T allele confers marginal protection for early stage 1B but risk for stage II of cervical cancer.


Subject(s)
Genetic Predisposition to Disease/genetics , Polymorphism, Single Nucleotide/genetics , Promoter Regions, Genetic/genetics , Transforming Growth Factor beta1/genetics , Uterine Cervical Neoplasms/genetics , Adult , Deoxycytidine/genetics , Female , Gene Frequency/genetics , Genotype , Heterozygote , Homozygote , Humans , India , Middle Aged , Neoplasm Staging , Odds Ratio , Risk Factors , Smoking/adverse effects , Thymidine/genetics , Tobacco, Smokeless/adverse effects , Uterine Cervical Neoplasms/pathology
15.
Biochemistry ; 48(47): 11304-11, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19839646

ABSTRACT

A base flipping conformation is found in many biological processes, including DNA repair and DNA and RNA modification processes. To investigate the dynamics and energetics of this unusual conformation in a double helix, base flipping induced by the base pair analogues of deoxyadenosine and deoxycytidine derivatives tethering a phenyl or naphthyl group was investigated. DNA strands bearing the base pair analogues stabilized the base flipping conformation of a complementary RNA, resulting in a site-specific hydrolysis by specific base catalysis. Measurements of the hydrolysis rate and the thermal stability of DNA/RNA duplexes suggested an unconstrained flexibility of the flipped-out ribonucleotide. As established in the base flipping by DNA repair and DNA and RNA modification enzymes, the results suggested that base flipping occurred in competition with base pair formation. In addition, the deoxycytidine derivatives discriminated G from I (inosine), with respect to the base pair interaction energy, as observed for a damaged base or a weakened base pair search by DNA repair proteins. The base pair mimic nucleosides would be useful for investigating the base flipping conformation under the equilibrium with base pairing.


Subject(s)
Base Pairing , Molecular Mimicry , Nucleic Acid Conformation , Nucleosides/chemistry , Nucleosides/metabolism , Base Sequence , Binding Sites , Computer Simulation , DNA/chemistry , DNA/genetics , DNA/metabolism , DNA Repair , Deoxyadenosines/chemistry , Deoxyadenosines/genetics , Deoxyadenosines/metabolism , Deoxycytidine/chemistry , Deoxycytidine/genetics , Deoxycytidine/metabolism , Hydrolysis , Nucleosides/genetics , RNA/chemistry , RNA/genetics , RNA/metabolism , Thermodynamics
16.
Stat Med ; 28(21): 2709-22, 2009 Sep 20.
Article in English | MEDLINE | ID: mdl-19572260

ABSTRACT

Non-tumor cell-based model systems have recently gained interest in pharmacogenetic research as a hypothesis generating tool. The hypotheses generated from these model systems can be followed up in functional studies, or tested in individuals taking the same investigational agents. The current cellular phenotypes (e.g. cytotoxicity) of interest in these studies are based on the effects of an individual dosage of a drug on the cell lines, or a summary of results at many dosages of a drug (e.g. dose that inhibits 50 per cent of cell growth, GI 50). A more complete analysis of the impact of genetic variation on all aspects of the dose-response curve may lend additional insight into the pharmacogenomics of a particular drug. This paper illustrates the use of a Bayesian hierarchical nonlinear model for the analysis of pharmacogenomic data with cytotoxicity endpoints. The model is illustrated with cytotoxicity and expression data collected on cell lines from a pharmacogenomic study of the drug gemcitabine. By completing an analysis based on the entire dose-response curve, we were able to detect additional genes that affect not only the GI 50, but also the slope of the curve, which reflects the therapeutic index of the drug. Simulation studies also demonstrate that in comparison with the analyses based on the commonly used summary measure GI 50, investigation of the impact of genetic variation on all aspects of the cytotoxicity dose-response curve is more informative, and more powerful with respect to detecting the effect of gene expression on cytotoxicity.


Subject(s)
Bayes Theorem , Drug-Related Side Effects and Adverse Reactions/genetics , Genetic Variation , Antimetabolites, Antineoplastic/therapeutic use , Deoxycytidine/analogs & derivatives , Deoxycytidine/genetics , Deoxycytidine/therapeutic use , Gene Expression , Humans , Models, Statistical , Pharmacogenetics , Gemcitabine
17.
Vaccine ; 27(14): 2030-6, 2009 Mar 23.
Article in English | MEDLINE | ID: mdl-19428826

ABSTRACT

Porcine epidemic diarrhea virus (PEDV) is a causative agent of severe diarrhea which leads to death in piglets. Because of the high mortality which is up to 100% in suckling piglets, PED is an important porcine disease in Korea. In this study, we developed a prophylactic candidate using single-chain Fvs to prevent the PEDV infection. ScFvs of mouse monoclonal antibody which was verified to neutralize PEDV was expressed in Escherichia coli expression system. After the confirmation of PEDV neutralizing activity of purified recombinant scFvs by VN test, scFvs were expressed on the surface of E. coli cells. The signal sequence and autotransporter beta domain of protease IgA (IgAP) of Neisseria gonorrhoeae were introduced to endow scFvs with the direction to the cell surface and the support as a transmembrane domain. 5x10(6)CFU of E. coli expressing scFvs against PEDV showed promising result of 94% foci reduction compared to wild type E. coli. This result demonstrated that E. coli expressing scFvs on the cell surface retained functional potency of parent antibody and therefore blocked PEDV infection into target cells in vitro. This in vitro assay result proposes the perspective of recombinant E. coli cells expressing scFvs as a novel prophylactic against PEDV infection.


Subject(s)
Antibodies, Monoclonal/immunology , Coronavirus Infections/prevention & control , Escherichia coli/immunology , Immunoglobulin Fragments/immunology , Porcine epidemic diarrhea virus/immunology , Swine Diseases/prevention & control , Amino Acid Sequence , Animals , Antibodies, Monoclonal/biosynthesis , Antibodies, Monoclonal/genetics , Antibody Specificity , Cross Reactions , Deoxycytidine/genetics , Epitopes/immunology , Escherichia coli/genetics , Immunoglobulin Fragments/biosynthesis , Immunoglobulin Fragments/genetics , Molecular Sequence Data , Neutralization Tests , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Serine Endopeptidases/immunology , Swine Diseases/virology
18.
Drug Metab Pharmacokinet ; 24(6): 553-6, 2009.
Article in English | MEDLINE | ID: mdl-20045991

ABSTRACT

Cytidine deaminase, encoded by the CDA gene, catalyzes anti-cancer drugs gemcitabine and ara-C into their respective inactive metabolites. In CDA, two functionally significant non-synonymous polymorphisms, 79A>C (Lys27Gln) and 208G>A (Ala70Thr), have been found and their minor allele frequencies (MAFs) were reported in Japanese and Chinese patients and a relatively small numbers of healthy volunteers in Caucasians and Africans. In this study, we determined the MAFs of both polymorphisms in 200 healthy volunteers of Koreans, along with 206 Japanese, 200 Chinese-Americans, 150 Caucasian-Americans and 150 African-Americans to reveal ethnic differences. MAFs of 79A>C (Lys27Gln) were 0.153 in Koreans and 0.327 in Caucasian-Americans, 0.204 in Japanese, 0.155 in Chinese-Americans and 0.087 in African-Americans. MAFs of 208G>A (Ala70Thr) were 0.005 in Koreans and 0.022 in Japanese and the minor allele was not detected in Chinese-Americans, Caucasian-Americans or African-Americans. Thus possibly, MAF of 208G>A in Japanese is likely to be somewhat higher than in Koreans and Chinese-Americans. These data would provide fundamental and useful information for pharmacogenetic studies on cytidine deaminase-catalyzing drugs.


Subject(s)
Black People/genetics , Black or African American/genetics , Cytidine Deaminase/genetics , Gene Frequency , Polymorphism, Genetic , Polymorphism, Single Nucleotide , Alleles , Antimetabolites, Antineoplastic , Antirheumatic Agents/pharmacology , Asian People/genetics , Cytarabine/pharmacology , Cytidine Deaminase/metabolism , Deoxycytidine/analogs & derivatives , Deoxycytidine/genetics , Genetic Predisposition to Disease , Genotype , Humans , Pharmacogenetics , White People/ethnology , Gemcitabine
19.
Mod Pathol ; 21(11): 1337-44, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18622385

ABSTRACT

Alterations in methylation of CpG dinucleotides at the 5 position of deoxycytidine residues (5(m)C) are a hallmark of cancer cells, including testicular germ cell tumors. Virtually all testicular germ cell tumors are believed to be derived from intratubular germ cell neoplasia unclassified (IGCNU), which is thought to arise from primordial germ cells. Prior studies revealed that seminomas contain reduced levels of global DNA methylation as compared with nonseminomatous germ cell tumors. Smiraglia et al have proposed a model whereby seminomas arise from IGCNU cells derived from primordial germ cells that have undergone 5(m)C erasure, and nonseminomas arise from IGCNU cells derived from primordial germ cells that have already undergone de novo methylation after the original erasure of methylation and contain normal 5(m)C levels. Yet the methylation status of IGCNU has not been determined previously. We used immunohistochemical staining against 5(m)C to evaluate global methylation in IGCNU and associated invasive testicular germ cell tumors. Strikingly, staining for 5(m)C was undetectable (or markedly reduced) in the majority of IGCNU and seminomas, yet there was robust staining in nonseminomatous germ cell tumors. The lack of staining for 5(m)C in IGCNU and seminomas was also found in mixed germ cell tumors containing both seminomatous and nonseminomatous components. Lack of 5(m)C staining was not related to a lack of the maintenance methyltransferase (DNA methyltransferase 1) protein. We conclude that testicular germ cell tumors are derived in most cases from IGCNU cells that have undergone developmentally programmed 5(m)C erasure and that the degree of subsequent de novo methylation is most closely related to the differentiation state of the neoplastic cells. That is, IGCNU cells and seminoma cells remain unmethylated, whereas all other histological types appear to arise after de novo methylation.


Subject(s)
DNA Methylation , Gene Silencing , Seminiferous Tubules/pathology , Seminoma/genetics , Testicular Neoplasms/genetics , Adolescent , Adult , Child , Child, Preschool , DNA, Neoplasm/chemistry , Deoxycytidine/genetics , Fluorescent Antibody Technique, Direct , Humans , Infant , Male , Middle Aged , Repressor Proteins/metabolism , Seminoma/metabolism , Seminoma/pathology , Spermatozoa/pathology , Testicular Neoplasms/metabolism , Testicular Neoplasms/pathology , Young Adult
20.
J Exp Med ; 203(2): 319-23, 2006 Feb 20.
Article in English | MEDLINE | ID: mdl-16476771

ABSTRACT

Somatic hypermutation of Ig genes enables B cells of the germinal center to generate high-affinity immunoglobulin variants. Key intermediates in somatic hypermutation are deoxyuridine lesions, introduced by activation-induced cytidine deaminase. These lesions can be processed further to abasic sites by uracil DNA glycosylase. Mutagenic replication of deoxyuridine, or of its abasic derivative, by translesion synthesis polymerases is hypothesized to underlie somatic hypermutation. Rev1 is a translesion synthesis polymerase that in vitro incorporates uniquely deoxycytidine opposite deoxyuridine and abasic residues. To investigate a role of Rev1 in mammalian somatic hypermutation we have generated mice deficient for Rev1. Although Rev1-/- mice display transient growth retardation, proliferation of Rev1-/- LPS-stimulated B cells is indistinguishable from wild-type cells. In mutated Ig genes from Rev1-/- mice, C to G transversions were virtually absent in the nontranscribed (coding) strand and reduced in the transcribed strand. This defect is associated with an increase of A to T, C to A, and T to C substitutions. These results indicate that Rev1 incorporates deoxycytidine residues, most likely opposite abasic nucleotides, during somatic hypermutation. In addition, loss of Rev1 causes compensatory increase in mutagenesis by other translesion synthesis polymerases.


Subject(s)
Deoxycytidine/genetics , Genes, Immunoglobulin , Guanine , Nucleotidyltransferases/deficiency , Point Mutation , Somatic Hypermutation, Immunoglobulin/genetics , Animals , B-Lymphocytes/enzymology , B-Lymphocytes/metabolism , DNA-Directed DNA Polymerase , Deoxycytidine/metabolism , Guanine/metabolism , Immunoglobulin D/genetics , Immunoglobulin M/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Nucleotidyltransferases/genetics , Uracil-DNA Glycosidase/genetics , Uracil-DNA Glycosidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...